Exploring T-Cell Fitness Strategies to Optimize Clinical Outcomes in RRMM

Exploring T-Cell Fitness Strategies to Optimize Clinical Outcomes in RRMM

Panelists discuss how bridging strategies such as selinexor, immunomodulatory drugs (IMiDs), and, potentially, immune checkpoint inhibitors (ICIs) can preserve or enhance T-cell fitness prior to chimeric antigen receptor T-cell therapy (CAR T), offering a dual benefit of disease control and improved therapeutic response in relapsed/refractory multiple myeloma (RRMM) patients.

CAR T-Cell Therapy: New Advances Move On Past Setbacks

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant excitement in both the medical and investment communities in recent years, its success has predominantly been confined to treating B-cell leukemias and lymphomas. To assess the current state of CAR T-cell therapy—including advancements in manufacturing …

Genezen, Optieum to develop CAR T-cell therapy for glioblastoma

Optieum Biotechnologies and Genezen are teaming up to help develop OPTF01, an experimental cell therapy for glioblastoma, an aggressive form of glioma. “Partnering with Genezen’s team of experts ensures that critical materials for our groundbreaking therapies are manufactured to the highest standards, accelerating our progress toward delivering next-generation therapies for glioblastoma and other solid tumors,” Shun Nishioka, CEO of Optieum, sai…